Innate Pharma Takes Back Rights and Sanofi Considers Investment

Innate Pharma regains rights to SAR443579/IPH6101, an ANKET® therapy targeting CD123 for acute myeloid leukemia, following the restructuring of the 2016 agreement with Sanofi. Sanofi could invest up to €15 million in Innate through a potential capital increase, subject to favorable market conditions.

Sanofi continues to explore SAR'514/IPH6401, targeting BCMA, for autoimmune indications. The Phase 1/2 clinical trial for SAR'579/IPH6101 shows clinical benefit and favorable tolerability. Sanofi has already advanced this therapy to Phase 2.

Innate remains eligible for more than €1 billion in payments related to research and development milestones. The 2022 agreement with Sanofi remains in effect.